| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a6ae2dfb110ebafabda61f5dc76d45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0860e138280564a879cb6b01a1c298a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b404330c47529bb8a0389ee60727c48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_985e586742507c77adffd57be9bc530e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 |
| filingDate |
2010-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec040cb019a8f1eddb0b497306937bc2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a7e5da6f35438dd2a3a7432d4394c40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02a35f9d8664fbf33bdd2ed3317df6ff |
| publicationDate |
2013-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8372978-B2 |
| titleOfInvention |
Salts of methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate |
| abstract |
Mucic acid salts of a compound represented by the following structural formula: n nare disclosed. In particular, single crystalline mucic acid salts of the compound represented by structural formula (I) are characterized by a variety of properties and physical measurements. Methods of producing the mucic acid salts, using the salts to antagonize one or more aspartic proteases, and methods of treating a number of aspartic protease mediated disorders using the salts are described herein. |
| priorityDate |
2009-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |